Altogether, our study reveals for the first time that co-targeting of N-Myc and Bcl-2 by JQ1/ABT-263 combination is a novel and effective strategy specifically for MYCN-amplified SCLC. The gene discussed is BCL2; the disease is small cell lung carcinoma.